Maxinject (Cefepime Dihydrochloride Monohydrate)

Cefepime belongs to the fourth‑generation cephalosporin class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final stage of peptidoglycan synthesis, weakening the wall and causing bacterial lysis, which eliminates both Gram‑negative and many Gram‑positive pathogens.

The exact dose of Maxinject is set by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. No fixed regimen is provided here; dosing must be individualized and documented in the patient’s medical record.

Cefepime’s pregnancy category is listed as unknown, and safety data are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their healthcare provider before administration.

To request Maxinject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Compared with earlier‑generation cephalosporins, cefepime offers broader activity against resistant Gram‑negative organisms, including Pseudomonas aeruginosa, while retaining activity against many Gram‑positive bacteria. It is often chosen over carbapenems for certain hospital‑acquired infections when susceptibility data support its use.

Maxinject should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Maxinject is supplied as a sterile injectable solution for intravenous use. It must be reconstituted with the appropriate diluent, then administered by slow IV infusion over the time period recommended by the prescriber, usually ranging from 30 minutes to 1 hour, depending on the clinical situation.

The most serious adverse events include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, seizures (especially in patients with renal impairment or high plasma levels), and significant renal toxicity when combined with other nephrotoxic drugs.

Patients with a known hypersensitivity to cefepime, other cephalosporins, or any β‑lactam antibiotics should avoid Maxinject. Caution is also required for individuals with severe renal impairment who have not had dose adjustments, and for those with a history of seizures or central nervous system disorders.